We are live on ! Find out more
CGTX icon

Cognition Therapeutics

32 hedge funds and large institutions have $13.8M invested in Cognition Therapeutics in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more capital invested

Capital invested by funds: $10.1M → $13.8M (+$3.72M)

6% less funds holding

Funds holding: 3432 (-2)

7.41% less ownership

Funds ownership: 31.81%24.4% (-7.4%)

14% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 7

20% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 5

Holders
32
Holders Change
-2
Holders Change %
-5.88%
% of All Funds
0.51%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
6
Reduced
7
Closed
5
Calls
Puts
Net Calls
Net Calls Change

CGTX Hedge Fund Activity: Q1 2023 in Review

32 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q1 2023, worth a combined $13.8M — up 37% from $10.1M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of CGTX and 4 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 6 added.

The largest buyer was Vanguard Group, adding an estimated $188K. The largest seller was Pathstone Family Office, cutting an estimated $4.21M.

  • 32 institutional investors held Cognition Therapeutics (CGTX) as of Q1 2023, down from 34 in Q4 2022.
  • Funds reported $13.8M of Cognition Therapeutics stock for Q1 2023, up 37% quarter-over-quarter.
  • 4 funds opened new Cognition Therapeutics positions in Q1 2023 and 5 closed out, a net change of -1 holder.
  • The largest Cognition Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $188K added.
  • The largest Cognition Therapeutics seller in Q1 2023 was Pathstone Family Office, an estimated $4.21M sold.

Based on aggregated 13F filings for Q1 2023.